GeneReach Biotechnology (4171) - Net Assets
Based on the latest financial reports, GeneReach Biotechnology (4171) has net assets worth NT$581.48 Million TWD (≈ $18.32 Million USD) as of June 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (NT$858.12 Million ≈ $27.04 Million USD) and total liabilities (NT$276.64 Million ≈ $8.72 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GeneReach Biotechnology strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | NT$581.48 Million |
| % of Total Assets | 67.76% |
| Annual Growth Rate | 11.45% |
| 5-Year Change | -45.16% |
| 10-Year Change | N/A |
| Growth Volatility | 36.0 |
GeneReach Biotechnology - Net Assets Trend (2017–2025)
This chart illustrates how GeneReach Biotechnology's net assets have evolved over time, based on quarterly financial data. For live market cap and overall valuation, see GeneReach Biotechnology (4171) market capitalisation.
Annual Net Assets for GeneReach Biotechnology (2017–2025)
The table below shows the annual net assets of GeneReach Biotechnology from 2017 to 2025. Also explore GeneReach Biotechnology (4171) equity growth momentum to track the company's year-over-year net asset growth rate.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | NT$596.72 Million ≈ $18.80 Million |
-17.75% |
| 2024-12-31 | NT$725.49 Million ≈ $22.86 Million |
-15.88% |
| 2023-12-31 | NT$862.44 Million ≈ $27.17 Million |
-21.79% |
| 2022-12-31 | NT$1.10 Billion ≈ $34.74 Million |
+1.34% |
| 2021-12-31 | NT$1.09 Billion ≈ $34.28 Million |
+26.85% |
| 2020-12-31 | NT$857.76 Million ≈ $27.02 Million |
+44.64% |
| 2019-12-31 | NT$593.05 Million ≈ $18.68 Million |
+90.60% |
| 2018-12-31 | NT$311.15 Million ≈ $9.80 Million |
+24.15% |
| 2017-12-31 | NT$250.63 Million ≈ $7.90 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to GeneReach Biotechnology's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 3409700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | NT$779.79 Million | 132.91% |
| Total Equity | NT$586.73 Million | 100.00% |
GeneReach Biotechnology Competitors by Market Cap
The table below lists competitors of GeneReach Biotechnology ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Abko Co. Ltd
KQ:129890
|
$29.20 Million |
|
Horizon Space Acquisition I Corp. Ordinary Shares
NASDAQ:HSPO
|
$29.21 Million |
|
China Crystal New Material
KQ:900250
|
$29.22 Million |
|
Hub Cyber Security Ltd. Ordinary Shares
NASDAQ:HUBC
|
$29.22 Million |
|
Auking Mining Ltd
AU:AKN
|
$29.19 Million |
|
Skyline Builders Group Holding Limited Class A Ordinary Shares
NASDAQ:SKBL
|
$29.19 Million |
|
DK&D Co.Ltd
KQ:263020
|
$29.19 Million |
|
Quickstep Holdings Ltd
AU:QHL
|
$29.18 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in GeneReach Biotechnology's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 716,980,000 to 586,728,000, a change of -130,252,000 (-18.2%).
- Net loss of 110,281,000 reduced equity.
- Share repurchases of 17,305,000 reduced equity.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | NT$-110.28 Million | -18.8% |
| Share Repurchases | NT$17.30 Million | -2.95% |
| Other Changes | NT$-2.67 Million | -0.45% |
| Total Change | NT$- | -18.17% |
Book Value vs Market Value Analysis
This analysis compares GeneReach Biotechnology's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.59x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
- The price-to-book ratio has decreased from 2.30x to 1.59x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2017-12-31 | NT$7.09 | NT$16.30 | x |
| 2018-12-31 | NT$8.10 | NT$16.30 | x |
| 2019-12-31 | NT$13.29 | NT$16.30 | x |
| 2020-12-31 | NT$14.13 | NT$16.30 | x |
| 2021-12-31 | NT$17.91 | NT$16.30 | x |
| 2022-12-31 | NT$18.01 | NT$16.30 | x |
| 2023-12-31 | NT$14.48 | NT$16.30 | x |
| 2024-12-31 | NT$12.48 | NT$16.30 | x |
| 2025-12-31 | NT$10.24 | NT$16.30 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently GeneReach Biotechnology utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -18.80%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -47.38%
- • Asset Turnover: 0.26x
- • Equity Multiplier: 1.50x
- Recent ROE (-18.80%) is below the historical average (4.17%), suggesting potential challenges in capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2017 | -19.20% | -30.97% | 0.26x | 2.41x | NT$-73.19 Million |
| 2018 | 9.89% | 15.24% | 0.27x | 2.40x | NT$-313.60K |
| 2019 | 13.89% | 21.10% | 0.48x | 1.37x | NT$21.63 Million |
| 2020 | 31.65% | 30.02% | 0.69x | 1.53x | NT$175.98 Million |
| 2021 | 35.88% | 37.21% | 0.60x | 1.60x | NT$271.64 Million |
| 2022 | 20.73% | 29.51% | 0.46x | 1.52x | NT$114.57 Million |
| 2023 | -19.98% | -73.75% | 0.19x | 1.41x | NT$-249.48 Million |
| 2024 | -16.56% | -57.50% | 0.19x | 1.49x | NT$-190.43 Million |
| 2025 | -18.80% | -47.38% | 0.26x | 1.50x | NT$-168.95 Million |
Industry Comparison
This section compares GeneReach Biotechnology's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $1,705,037,800
- Average return on equity (ROE) among peers: 1.20%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| GeneReach Biotechnology (4171) | NT$581.48 Million | -19.20% | 0.48x | $29.20 Million |
| Apex Biotechnology Corp (1733) | $1.66 Billion | 5.14% | 0.62x | $95.26 Million |
| Sinphar Pharmaceutical Co Ltd (1734) | $3.72 Billion | 9.84% | 0.66x | $187.56 Million |
| Panion & BF Biotech Inc (1760) | $835.25 Million | 10.84% | 0.49x | $144.79 Million |
| Chunghwa Chemical Synthesis & Biotech Co Ltd (1762) | $1.19 Billion | 20.52% | 0.94x | $81.55 Million |
| SYN-Tech Chem & Pharm Co Ltd (1777) | $2.20 Billion | 13.43% | 0.26x | $103.54 Million |
| Level Biotechnology (3118) | $513.75 Million | 9.23% | 0.46x | $32.10 Million |
| GenMont Biotech Inc (3164) | $1.60 Billion | -24.18% | 0.09x | $42.95 Million |
| Medigen Biotechnology (3176) | $3.46 Billion | -15.61% | 0.30x | $166.12 Million |
| Sagittarius Life Science (3205) | $455.42 Million | -16.29% | 0.27x | $98.53 Million |
| Genovate Biotechnology Co Ltd (4130) | $1.41 Billion | -0.87% | 0.11x | $115.03 Million |
About GeneReach Biotechnology
GeneReach Biotechnology Corp. develops, manufactures, and markets products for applied nucleic acid detection technology in Taiwan. The company offers various equipment, such as POCKIT Central Nucleic Acid Analyzer, POCKIT Micro Series, taco mini Automatic Nucleic Acid Extraction System, taco Prep Homogenization System, and cubee Mini-Centrifuge; reagents and consumables, including Human IVD Assa… Read more